Download PDF
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2022; 58(01): 022-026
DOI: 10.1055/s-0041-1731970
Original Article

Exploring the Serum Level of RE1 Silencing Transcription Factor in Alzheimer's Disease

Shashank Shekhar
1   Department of Biophysics, All India Institute of Medical Sciences, New Delhi, India
,
Manjari Tripathi
2   Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
,
A.B. Dey
3   Department of Geriatric Medicine, All India Institute of Medical Sciences, New Delhi, India
,
Sharmistha Dey
3   Department of Geriatric Medicine, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objectives The aim of this study was to evaluate the serum RE1 silencing transcription factor (REST) level in Alzheimer's disease (AD), mild cognitive impairment (MCI), and elderly controls by using surface plasmon resonance (SPR) technology.

Materials and Methods In this case–control study of 133 subjects, 49 patients with AD, 49 patients with MCI, and 35 elderly controls were recruited. The REST protein concentrations were evaluated by SPR. The resonance unit for each sample was recorded and the concentration of serum REST of study group was derived from the standard curve. All the experiments were done in triplicates. Statistical analysis was done and p-value of < 0.05 was considered as statistically significant.

Results A significant difference was observed in the Montreal Cognitive Assessment score, Hindi Mental State Examination scale (HMSE) score education, disease duration, and gender among the groups. A significant (p>0.0001) difference in the duration of disease between AD and MCI was observed. It was observed that the mean concentration of serum REST was not significantly (p = 0.266) different among the groups.

Conclusion This study first time evaluated the serum levels of REST in AD, MCI and age-matched elderly controls. The rest levels were similar in all groups; however, it can provide a new direction to future blood-based biomarker studies of REST.

Keywords

Alzheimer's disease - serum RE1 silencing transcription factor - mild cognitive impairment - surface plasmon resonance

Author Contributions

S.S. performed the experimental work and wrote the manuscript; A.B.D. and M.T. provided the patients samples, and S.D. designed the work and edited the manuscript.




Publication History

Article published online:
08 November 2021

© 2021. National Academy of Medical Sciences (India). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Jotheeswaran A, Girish N. et al. The Dementia India Report: Prevalence, Impact, Costs and Services for Dementia. Executive Summary. New Delhi, India: Alzheimer's and Related Disorders Society of India (ARDSI); 2010
    Google Scholar
  • 2 Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362 (04) 329-344
    CrossrefPubMedGoogle Scholar
  • 3 Lodato E. Priority Medicines for Europe and the World “A Public Health Approach to Innovation” Update on the 2004 Background Paper. 13: 1-122
    Google Scholar
  • 4 Lu T, Aron L, Zullo J. et al. REST and stress resistance in ageing and Alzheimer's disease. Nature 2014; 507 (7493) 448-454
    CrossrefPubMedGoogle Scholar
  • 5 Nho K, Kim S, Risacher SL. et al. MIRAGE (Multi-Institutional Research on Alzheimer Genetic Epidemiology) Study, AddNeuroMed Consortium, Indiana Memory and Aging Study, Alzheimer's Disease Neuroimaging Initiative. Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol 2015; 77 (03) 547-552
    CrossrefPubMedGoogle Scholar
  • 6 A Hindi version of the MMSE: The development of a cognitive screening instrument for a largely illiterate rural elderly population in India - Ganguli - 1995 - International Journal of Geriatric Psychiatry - Wiley Online Library. Available at:https://onlinelibrary.wiley.com/doi/abs/10.1002/gps.930100505. Accessed June 16, 2021
  • 7 O'Caoimh R, Timmons S, Molloy DW. Screening for mild cognitive impairment: comparison of “MCI Specific” screening instruments. J Alzheimers Dis 2016; 51 (02) 619-629
    CrossrefPubMedGoogle Scholar
  • 8 McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34 (07) 939-944
    CrossrefPubMedGoogle Scholar
  • 9 O'Bryant SE, Gupta V, Henriksen K. et al. STAR-B and BBBIG working groups. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement 2015; 11 (05) 549-560
    CrossrefPubMedGoogle Scholar
  • 10 Shekhar S, Yadav SK, Rai N. et al. 5-LOX in Alzheimer's disease: potential serum marker and in vitro evidences for rescue of neurotoxicity by its inhibitor YWCS. Mol Neurobiol 2018; 55 (04) 2754-2762
    CrossrefPubMedGoogle Scholar
  • 11 Thiel G, Lietz M, Cramer M. Biological activity and modular structure of RE-1-silencing transcription factor (REST), a repressor of neuronal genes. J Biol Chem 1998; 273 (41) 26891-26899
    CrossrefPubMedGoogle Scholar
  • 12 Meyer K, Feldman HM, Lu T. et al. REST and neural gene network dysregulation in iPSC models of Alzheimer's disease. Cell Rep 2019; 26 (05) 1112-1127.e9
    CrossrefPubMedGoogle Scholar
  • 13 Goetzl EJ, Boxer A, Schwartz JB. et al. Low neural exosomal levels of cellular survival factors in Alzheimer's disease. Ann Clin Transl Neurol 2015; 2 (07) 769-773
    CrossrefPubMedGoogle Scholar
  • 14 Abner EL, Jicha GA, Shaw LM, Trojanowski JQ, Goetzl EJ. Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging. Ann Clin Transl Neurol 2016; 3 (05) 399-403
    CrossrefPubMedGoogle Scholar
  • 15 Russo I, Bubacco L, Greggio E. Exosomes-associated neurodegeneration and progression of Parkinson's disease. Am J Neurodegener Dis 2012; 1 (03) 217-225
    PubMedGoogle Scholar
  • 16 Marzesco A-M, Janich P, Wilsch-Bräuninger M. et al. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 2005; 118 (Pt 13) 2849-2858
    CrossrefPubMedGoogle Scholar
  • 17 Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer of toxic proteins associated with neurodegenerative diseases?. Front Physiol 2012; 3: 124
    CrossrefPubMedGoogle Scholar